electroCore seeks FDA clearance for Quell to treat chemotherapy-induced neuropathy
ECOR•electroCore submitted a 510(k) application seeking FDA clearance for Quell to treat chronic chemotherapy-induced peripheral neuropathy. The submission is supported by two clinical studies involving 168 subjects, including a 142-subject randomized controlled trial.
1. FDA application
electroCore submitted a 510(k) application to the FDA seeking clearance for Quell to treat chronic chemotherapy-induced peripheral neuropathy. The submission is supported by two clinical studies involving 168 subjects, including a 142-subject randomized controlled trial.
